The role of hemoglobin-cytarabine in the selective death of acute myeloid leukemia cells

Acute myeloid leukemia (AML) is a blood cancer with very poor prognosis, especially for patients older than 60 years of age. This is in part because of the severe toxicity of medicines available. Less harmful medicines are needed to better treat older patients. Therapure Biopharma Inc. has chemically linked the standard toxic chemotherapy medicine called cytarabine […]

Read More